** Gene therapy company MeiraGTx Holdings' shares MGTX.O rise 30.3% to $8.36 - highest since June 2023
** MGTX says it will collaborate with Hologen to form a joint venture called Hologen Neuro AI to develop experimental gene therapy AAV-GAD to treat Parkinson's disease
** Parkinson's disease is a brain condition that causes problems with movement, mental health, sleep, pain and other health issues
** MGTX will receive $200 million in upfront payment for the venture and $230 million to develop the gene therapy AAV-GAD, which is currently in late-stage development
** MGTX says it will retain 30% ownership in the joint venture and will lead all clinical development and manufacturing
** Separately, MGTX posts 2024 revenue of $33.28 mln, compared to $14.02 mln a year earlier
** Up to last close, MGTX had risen 5.6% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。